Odyssey Health, Inc.
For the period ended Apr 30, 2026. Filed Jun 12, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Apr 30, 2026 · Filed Jun 12, 2026
ODYYStored price and day change unavailable
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)
| For the Three Months Ended April 30, | For the Nine Months Ended April 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| General and administrative expense | $297,554 | $129,055 | $782,687 | $865,075 |
| Loss from operations | (297,554) | (129,055) | (782,687) | (865,075) |
| Loss from change in fair value of Oragenics, Inc. common stock | – | (61,357) | – | (432,053) |
| Interest expense | (527,551) | (61,395) | (1,035,315) | (193,611) |
| Financing costs | – | – | (3,080,023) | – |
| Change in fair value of derivative liability | 1,505,581 | – | 1,503,652 | – |
| Gain on extinguishment of accounts payable | 85,369 | – | 85,369 | – |
| Other income (expense), net | 45 | 64 | (10,177) | (36) |
| Net income (loss) and comprehensive income (loss) | 765,890 | (251,743) | (3,319,181) | (1,490,775) |
| Basic net income (loss) and comprehensive income (loss) per share | $0.01 | $0.00 | $(0.03) | $(0.01) |
| Diluted net income (loss) and comprehensive income (loss) per share | $0.01 | $0.00 | $(0.03) | $(0.01) |
| Shares used for basic net income (loss) comprehensive income (loss) per share | 108,031,419 | 104,709,763 | 107,299,314 | 104,709,763 |
| Shares used for diluted net income (loss) comprehensive income (loss) per share | 186,674,907 | 104,709,763 | 107,299,314 | 104,709,763 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.